Table 2. The characteristics of patient with low SIRI versus high SIRI in the cohort.
| Characteristics | Low SIRI, n (%) | High SIRI, n (%) | P value |
|---|---|---|---|
| Age | 0.072 | ||
| ≤50 years | 141 (80.6) | 34 (19.4) | |
| >50 years | 76 (89.4) | 9 (10.6) | |
| Menopausal | 1.000 | ||
| Premenopausal | 132 (75.0) | 44 (25.0) | |
| Postmenopausal | 63 (75.0) | 21 (25.0) | |
| Pre-NACT T stage | 0.506 | ||
| T1–2 | 123 (84.8) | 22 (15.2) | |
| T3–4 | 94 (81.7) | 21 (18.3) | |
| Pre-NACT N stage | 0.126 | ||
| N0–1 | 71 (88.8) | 9 (11.2) | |
| N2–3 | 146 (81.1) | 34 (18.9) | |
| Pre-NACT TNM stage | 0.167 | ||
| IA–IIB | 51 (89.5) | 6 (10.5) | |
| IIIA–IIIC | 166 (81.8) | 37 (18.2) | |
| Tumor grade | 0.028 | ||
| I–II | 88 (89.8) | 10 (10.2) | |
| III | 55 (77.5) | 16 (22.5) | |
| LVI | 0.054 | ||
| No | 121 (79.6) | 31 (20.4) | |
| Yes | 82 (89.1) | 10 (10.9) | |
| Pathological N stage | 0.081 | ||
| N0–1 | 142 (80.7) | 34 (19.3) | |
| N2–3 | 75 (89.3) | 9 (10.7) | |
| ER | 0.005 | ||
| Negative | 72 (75.0) | 24 (25.0) | |
| Positive | 145 (88.4) | 19 (11.6) | |
| PR | 0.006 | ||
| Negative | 97 (77.0) | 29 (23.0) | |
| Positive | 120 (89.6) | 14 (10.4) | |
| HER2 | 0.579 | ||
| Negative | 126 (84.6) | 23 (15.4) | |
| Positive | 91 (82.0) | 20 (18.0) | |
| Molecular subtype | 0.023 | ||
| Luminal A | 61 (85.9) | 10 (14.1) | |
| Luminal B | 90 (90.0) | 10 (10.0) | |
| HER2 positive | 35 (71.4) | 14 (28.6) | |
| TNBC | 31 (77.5) | 9 (22.5) | |
| AR | 0.10 | ||
| Negative | 13 (72.2) | 5 (27.8) | |
| Positive | 116 (89.2) | 14 (10.8) | |
| Ki-67 | 0.10 | ||
| ≥30% | 110 (80.3) | 27 (19.7) | |
| <30% | 102 (87.9) | 14 (12.1) | |
| pCR | 0.772 | ||
| No | 162 (83.1) | 33 (16.9) | |
| Yes | 55 (84.6) | 10 (15.4) |
SIRI, systemic inflammation response index; pre-NACT, pre-neoadjuvant chemotherapy; TNM, tumor-node-metastasis; LVI, lymph vascular invasion; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer; AR, androgen receptor; pCR, pathological complete response.